Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of JP-2266 in Healthy Male Caucasian Subjects
NCT05172622Phase 1Unknown
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- Nov 2020
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in diabetes mellitus (DM) comparing JP-2266 with Placebo (2 arms). Primary endpoints: Number of adverse events and percentage of subjects at Day 19 and Maximum plasma concentration up to 72 hours. Status: unknown.
02
Drugs
JP-2266
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT05172622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05172622.